# Champions Oncology, Inc.: Form 10-Q for the period ended Jan 31, 2012

- Company: [Champions Oncology, Inc.](/companies/csbr.md) (CIK 771856)
- Form: 10-Q
- Filed: 2012-03-14
- Accepted by EDGAR: Mar 14, 2012, 14:58 ET
- Period: 2012-01-31
- Accession: 0001144204-12-014815
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/771856/000114420412014815/v304999_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/771856/000114420412014815/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2012-01-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2011-11-01 to 2012-01-31 | $930.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2011-05-01 to 2012-01-31 | $2.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2011-11-01 to 2012-01-31 | −$1.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2011-05-01 to 2012-01-31 | −$6.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2011-11-01 to 2012-01-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2011-05-01 to 2012-01-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2011-11-01 to 2012-01-31 | −$1.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2011-05-01 to 2012-01-31 | −$6.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2011-11-01 to 2012-01-31 | −$0.04 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2011-05-01 to 2012-01-31 | −$0.13 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2011-05-01 to 2012-01-31 | −$3.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2011-05-01 to 2012-01-31 | $371.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2011-05-01 to 2012-01-31 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2012-01-31 | $6.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2012-01-31 | $7.6m | us-gaap:AssetsCurrent |
| Total assets | at 2012-01-31 | $8.9m | us-gaap:Assets |
| Current liabilities | at 2012-01-31 | $3.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2012-01-31 | $4.1m | us-gaap:Liabilities |
| Shareholders' equity | at 2012-01-31 | −$3.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 20,059 characters.

*The following discussion of our historical results of operations and our liquidity and capital resources should be read in conjunction with the condensed consolidated financial statements and related notes that appear elsewhere in this report.*

### Forward-Looking Statements

This Quarterly Report on Form 10-Q, including Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking statements include, without limitation, statements regarding: proposed new programs; expectations that regulatory developments or other matters will not have a material adverse effect on our financial position, results of operations, or liquidity; statements concerning projections, predictions, expectations, estimates, or forecasts as to our business, financial and operational results, and future economic performance; and statements of management’s goals and objectives and other similar expressions concerning matters that are not historical facts. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions, as well as statements in future tense, identify forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to, those described in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2011, as updated in our subsequent reports filed with the SEC, including any updates found in Part II, Item 1A of this or other reports on Form 10-Q. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

### Overview and Recent Developments

Champions Oncology, Inc. (the “Company”), is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company’s Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice. The Company uses this technology to derive revenue for two customer groups: Personalized Oncology Solutions (“POS”), and Translational Oncology Solutions (“TOS”). POS assist physicians in developing personalized treatment options for their cancer patients through access to panels of expert medical professionals and tumor specific data. TOS offers a technology platform to pharmaceutical and biotechnology companies using proprietary Tumorgraft studies, which have been shown to be predictive of how drugs may perform in clinical settings.

As explained in Item 1, “Business” of our Form 10-K for the year ended April 30, 2011, our operations have recently been refocused to emphasize our POS and TOS lines of business. We also plan to continue our research and development efforts to expand our Tumorgraft Technology Platform in order to expand our TOS program.

In fiscal 2011, the Company modified its POS business strategy to focus on growing its core technology products, which includes Tumorgraft implants and drug studies. As a result, the Company significantly reduced the price of the core technology products to make the products affordable to a broader patient base. In addition, the Company has increased spending on sales and marketing efforts to support this strategy. The Company will continue to offer related personalized oncology services to our customers, including personalized tumor panels and gene sequencing, however, we expect future POS revenue growth to be driven by our core products.

During fiscal 2012, the Company started transitioning the laboratory activities that support the POS and TOS services to our facility in Baltimore, Maryland. To facilitate this strategy and support the increase in current and expected volume, we have invested in the infrastructure and increased our laboratory staff and are evaluating options to increase our lab capacity to meet the future demand. We believe that bringing these activities in house will significantly reduce the cost of providing our services and allow us to maintain a more aggressive pricing strategy. We expect the transition to be largely complete by the end of the first quarter of fiscal 2013.

### Operating Results

The following tables summarize our operating results for the periods presented below (dollars in thousands):

| Operating revenue: | For the Three Months Ended January 31, 2012 | % of Revenue | 2011 | % of% Revenue | Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Personalized oncology solutions | $649 | 27.1% | $1,419 | 50.6% | (54.3)% |
| Translational oncology solutions | 1,747 | 72.9 | 1,386 | 49.4 | 26.0 |
| Total operating revenue | 2,396 | 100.0 | 2,805 | 100.0 | (14.6) |
| **Costs and operating expenses:** |  |  |  |  |  |
| Cost of personalized oncology solutions | 528 | 22.0 | 725 | 25.8 | (27.2) |
| Cost of translational oncology solutions | 801 | 33.4 | 688 | 24.5 | 16.4 |
| Research and development | 930 | 38.8 | 434 | 15.5 | 114.3 |
| Sales and marketing | 623 | 26.0 | 239 | 8.5 | 160.7 |
| General and administrative | 1,287 | 53.7 | 1,505 | 53.7 | (14.5) |
| Total costs and operating expenses | 4,169 | 174.0 | 3,591 | 128.0 | 16.1 |
| Operating loss | $(1,773) | (74.0)% | $(786) | (28.0)% | 125.6% |

| Operating revenue: | For the Nine Months Ended January 31, 2012 | % of Revenue | 2011 | % of% Revenue | Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Personalized oncology solutions | $1,837 | 31.8% | $2,816 | 52.8% | (34.8)% |
| Translational oncology solutions | 3,931 | 68.2 | 2,522 | 47.2 | 55.9 |
| Total operating revenue | 5,768 | 100.0 | 5,338 | 100.0 | 8.1 |
| **Costs and operating expenses:** |  |  |  |  |  |
| Cost of personalized oncology solutions | 1,463 | 25.4 | 1,213 | 22.7 | 20.6 |
| Cost of translational oncology solutions | 1,904 | 33.0 | 1,399 | 26.2 | 36.1 |
| Research and development | 2,558 | 44.3 | 2,117 | 39.7 | 20.8 |
| Sales and marketing | 1,885 | 32.7 | 356 | 6.7 | 429.5 |
| General and administrative | 4,421 | 76.6 | 2,649 | 49.6 | 66.9 |
| Total costs and operating expenses | 12,231 | 212.0 | 7,734 | 144.9 | 58.1 |
| Operating loss | $(6,463) | (112.0)% | $(2,396) | (44.9)% | 169.7% |

### Operating Revenues

Operating revenues were $2.4 million and $2.8 million for the three months ended January 31, 2012 and 2011, respectively, and $5.8 million and $5.3 million for the nine months ended January 31, 2011 and 2010, respectively.

POS revenues were $0.6 million and $1.4 million for the three months ended January 31, 2012 and 2011, respectively, a decrease of $0.8 million, or 54 %. POS revenues were $1.8 million and $2.8 million for the nine months ended January 31, 2012 and 2011, respectively, a decrease of $1.0 million, or 35%. Panel revenue, a component of POS revenue, decreased $0.9 million and $1.0 million for the three and nine months ended January 31, 2012, respectively. This decrease is primarily attributable to a decrease in pricing per panel. Excluding panel revenue, POS revenue was $0.59 million and $0.5 million for three months ended January 31, 2012 and 2011, an increase of $0.09 million and $1.35 million and $1.32 million for nine months ended January 31, 2012 and 2011, respectively, an increase of $0.03 million. The Company experienced significantly higher volumes of implants and drug studies compared to the prior year. For the three months ended January 31, 2012, the Company performed 25 tumorgraft implants compared to one in the same quarter last year. For the nine months ended January 31, 2012, the Company performed 70 tumorgraft implants compared to nine in the prior year. For the three months ended January 31, 2012, the Company completed five drug studies compared to zero in the same quarter last year. For the nine months ended January 31, 2012, the Company completed nine drug studies compared to three in the prior year. However, the increase in volume was partially offset by a strategic decision to lower pricing for both the tumorgraft implants and drug studies.

TOS revenues were $1.7 million and $1.4 million for the three months ended January 31, 2012 and 2011, respectively, an increase of $0.3 million or 26%. TOS revenues were $3.9 million and $2.5 million for the nine months ended January 31, 2012 and 2011, respectively, an increase of $1.4 million or 56%. These increases in TOS revenues were due primarily to increased sales efforts and investments in growing our Tumorbank.

### Cost of POS

Cost of POS was $0.5 million and $0.7 million for the three months ended January 31, 2012 and 2011, respectively, a decrease of $0.2 million, or 27%. Cost of POS was $1.5 million and $1.2 million for the nine months ended January 31, 2012 and 2011, respectively, an increase of $0.3 million, or 21%. Gross margin for POS was 19% and 49% for the three months ended January 31, 2012 and 2011, respectively, and 20% and 57% for the nine months ended January 31, 2012 and 2011, respectively. In the fiscal third quarter, the Company has begun the transition of moving its laboratory work internally from a third party provider. While this has resulted in increased cost in the current quarter, it is expected to yield future savings. This laboratory transition in combination with the Company’s strategic decision to lower price points across service lines in the current year contributed to the declines in gross margin.

### Cost of TOS

Cost of TOS was $0.8 million and $0.7 million for the three months ended January 31, 2012 and 2011, respectively, an increase of $0.1 million, or 16%. Cost of TOS was $1.9 million and $1.4 million for the nine months ended January 31, 2012 and 2011, respectively, an increase of $0.5 million, or 36%. The increase in costs was due to the increased volume of TOS business. Gross margin for TOS was 54% and 50% for the three months ended January 31, 2012 and 2011, respectively, and 52% and 45% for the nine months ended January 31, 2012 and 2011, respectively. The increases in gross margin can be attributed to the mix and complexity of drug studies that were completed in the respective periods.

### Research and Development

Research and development expense was $0.9 million and $0.4 million for the three months ended January 31, 2012 and 2011, respectively, an increase of $0.5 million, or 114%. Research and development expense was $2.6 million and $2.1 million for the nine months ended January 31, 2012 and 2011, respectively, an increase of $0.5 million, or 21%. The increases from prior year periods are primarily related to increased costs resulting from our continued investment in our Tumorbank and technology platform.

### Sales and Marketing

Sales and marketing expense was $0.6 million and $0.2 million for the three months ended January 31, 2012 and 2011, respectively, an increase of $0.4 million, or 161%. Sales and marketing expense was $1.9 million and $0.4 million for the nine months ended January 31, 2012 and 2011, respectively, an increase of $1.5 million. The increases from prior year periods are primarily related to our continued investment in the infrastructure in POS, increases in our sales force, and increases in marketing costs.

### General and Administrative

General and administrative expense was $1.3 million and $1.5 million for the three months ended January 31, 2012 and 2011, respectively, a decrease of $0.2 million, or 15%. Stock-based compensation was $0.7 million and $1.2 million for the three months ended January 31, 2012 and 2011, respectively. Excluding stock-based compensation, general and administrative expenses were $0.5 million and $0.3 million for the three months ended January 31, 2012 and 2011, respectively, an increase of $0.2 million. General and administrative expense was $4.4 million and $2.6 million for the nine months ended January 31, 2012 and 2011, respectively, an increase of $1.8 million, or 67%. Stock-based compensation was $2.6 million and $1.6 million for the nine months ended January 31, 2012 and 2011, respectively. Excluding stock-based compensation, general and administrative expenses were $1.8 million and $1.0 million for the nine months ended January 31, 2012 and 2011, respectively, an increase of $0.8 million. The increases from the prior periods are related to the expansion of our infrastructure, the addition of our corporate offices in New Jersey, and other costs associated with the Company’s growth strategy.

### Other Income (Expense)

Other income was $0.05 million and $0.4 for the three months ended January 31, 2012 and 2011, respectively, a decrease of $0.3 million. Other income was $0.4 million and $1.3 million for the nine months ended January 31, 2012 and 2011, respectively, a decrease of $0.9 million. During the three and nine months ended January 31, 2012, the Company recognized income of $0.06 million and $0.3 million, respectively, for the change in fair value of warrants that are accounted for as liabilities on the unaudited condensed consolidated balance sheets and are described further below and in Note 5 to the accompanying unaudited condensed consolidated financial statements. In the prior year, other income primarily consisted of cash grants awarded to the Company under the Qualifying Therapeutic Discovery Project program administered under section 48D of the Internal Revenue Code which income was not repeated for the 2012 period.

### Liquidity and Capital Resources

Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements and other strategic initiatives. In the past, we have met these cash requirements through our cash and cash equivalents, working capital management and proceeds from certain private placements of our securities. As of January 31, 2012, we had working capital of $4.1 million and cash and cash equivalents of $6.5 million. We believe that our cash and cash equivalents on hand at January 31, 2012 are adequate to fund operations for at least the next twelve months.

On March 24, 2011, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale to the investors of an aggregate 12,533,333 shares of the Company’s common stock at a purchase price of $0.75 per share, or an aggregate of $9.4 million, of which, $0.5 million was sold to officers and directors of the Company. As part of this transaction, we issued warrants to purchase an aggregate 1,266,667 shares of common stock at an exercise price of $0.90 per share. These warrants expire five years after the closing date, which occurred on April 4, 2011. The Securities Purchase Agreement contains certain anti-dilution protections for the investors and certain registration rights with respect to the shares of common stock issued to the investors. Furthermore, investors will have the right to require the Company to repurchase the purchased common shares held (the “Put Option”) for cash for $0.75 per share upon a change of control or sale of substantially all of the company’s assets. The Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement.

The warrants issued in connection with the Securities Purchase Agreement contain certain exercise price reset provisions. Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its common stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the Securities Purchase Agreement).

If we require additional cash, there can be no assurance that management will be successful in raising additional capital on terms acceptable to us, if at all. Our ability to successfully complete a raise of capital will depend on the conditions of the capital markets and our financial condition and prospects. Even if we are able to successfully raise additional capital, such capital could be in the form of debt and could be at high interest rates and/or require us to comply with restrictive covenants that limit financial and business activities. In addition, even if we are able to successfully raise equity capital, this could dilute the interest of existing shareholders and/or be issued with preferential liquidation, dividend or voting rights to those currently held by our common stockholders

### Cash Flows

The following discussion relates to the major components of our cash flows:

#### Cash Flows from Operating Activities

Net cash used in operating activities was $3.7 million for the nine months ended January 31, 2012. Net cash provided by operating activities was $0.5 million for the nine months ended January 31, 2011. The increase of $4.2 million of cash used in operating activities was primarily due to higher working capital requirements.

#### Cash Flows from Investing Activities

Net cash used in investing activities was $371,000 and less than $47,000 for the nine months ended January 31, 2012 and 2011, respectively. Cash used for the nine months ended January 31, 2012 and 2011 relates to the purchase of property and equipment for both the operations of the Company and the establishment of our new corporate headquarters in Hackensack, New Jersey.

#### Cash Flows from Financing Activities

Net cash provided by financing activities was $98,000 for the nine months ended January 31, 2012, which relates to the exercise of warrants. Net cash used in financing activities was $71,000 for the nine months ended January 31, 2011, which primarily relates to the purchase of treasury stock.

### Critical Accounting Estimates and Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to apply methodologies and make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates of the Company include, among other things, accounts receivable realization, valuation allowances for deferred tax assets, valuation of goodwill, and stock compensation assumptions. Actual results could differ from those estimates. The Company’s critical accounting policies are summarized in the Company’s Annual Report on Form 10-K, filed with the SEC on July 15, 2011.

## Controls and procedures

As filed, 1,697 characters.

### Evaluation of Disclosure Controls and Procedures

It is management’s responsibility to establish and maintain “disclosure controls and procedures” as such term is defined in Rule 13a-15 under the Securities Exchange Act of 1934 (the “Exchange Act”). Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of a date within ninety (90) days of the filing date of this Form 10-Q quarterly report. Based on that evaluation, our management, including our Chief Executive Officer and our Chief Financial Officer, have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Form 10-Q at the reasonable assurance level in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 124 characters.

There have been no material changes in risk factors previously disclosed in our Form 10-K for the year ended April 30, 2011.

Filed Mar 14, 2012.
Source: SEC EDGAR, the filing index for accession 0001144204-12-014815. Last ingested by Listed: Nov 10, 2026, 03:33 ET. No prices; not investment advice.
